TAB-024

antibody from Creative Biolabs

Targeting: ITGAL CD11A, LFA-1

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Immunoprecipitation (Recommended by provider)

Flow cytometry (Recommended by provider)

Blocking/Neutralizing (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

TAB-024

Provider

Creative Biolabs

Product name

Anti-Human CD11A Recombinant Antibody (Efalizumab)

Antibody type

Monoclonal

Description

Recombinant monoclonal antibody to Human CD11A. Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.

Reactivity

Human

Host

Mouse

Storage

Store it under sterile conditions at -20¡ãC upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.